curonix home
OUR SOLUTION

main challenges in drug delivery across the blood-brain barrier.

  • The blood-brain barrier (BBB) is a specialized system of cells on the brain’s vasculature.
  • It maintains homeostasis and protects the brain from toxins and pathogens, but it also blocks the entry of most therapeutic agents.
  • More than 98% of drugs never reach the brain in therapeutically relevant concentrations.
  • Drug development for neurological diseases currently has the poorest success rates compared to other therapeutic areas.

using microbubble vibration.

Microbubbles, approximately 100 times smaller than a single hair, circulate through the brain vasculature after an intravenous injection. When exposed to focused ultrasound (FUS), they vibrate and interact with endothelial cells of the brain vasculature, resulting in modulation of the BBB. The precise control of FUS ensures that therapeutic agents for e.g. brain cancer or neurodegenerative diseases are delivered to the specific site of interest in the brain.

automated and controlled microbubble formation and administration.

Our microbubble injector system controls the formation of monodisperse microbubbles which are characterized by a predictable narrowband acoustic response, thereby enabling uniform and controlled FUS interactions. Additionally, the microbubble injector ensures precise dosing and controlled administration of microbubbles. This potentially improves the therapeutic efficacy, reproducibility, and safety of microbubble-enhanced FUS for drug delivery in the brain.

curix-alpha-in-MRI

Important notice: This technology is currently under development and has not yet been issued a CE certificate in accordance with the EU Medical Device Regulation. It is also not approved by the U.S. Food and Drug Administration for clinical use.